Cargando…
Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal non-Hodgkin lymphoma. The predominant subtype is diffuse large B-cell lymphoma (DLBCL), and no systematic lesion is identified at diagnosis. BTKi (Bruton’s tyrosine kinase inhibitor) has demonstrated significant clin...
Autores principales: | Liu, Ying, Sun, Jie, Tuo, Kangxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105325/ https://www.ncbi.nlm.nih.gov/pubmed/37069896 http://dx.doi.org/10.1159/000529315 |
Ejemplares similares
-
Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib
por: Cheng, Qiansong, et al.
Publicado: (2021) -
P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Lin, Zhiguang, et al.
Publicado: (2023) -
P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN(ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022) -
PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023) -
PB2337: SHORT-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH POMALIDOMIDE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Zhang, Zhipeng, et al.
Publicado: (2023)